Cargando…

Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data

BACKGROUND: Tamoxifen and raloxifene reduce the risk of breast cancer in women at elevated risk of disease, but the duration of the effect is unknown. We assessed the effectiveness of selective oestrogen receptor modulators (SERMs) on breast cancer incidence. METHODS: We did a meta-analysis with ind...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cuzick, Jack, Sestak, Ivana, Bonanni, Bernardo, Costantino, Joseph P, Cummings, Steve, DeCensi, Andrea, Dowsett, Mitch, Forbes, John F, Ford, Leslie, LaCroix, Andrea Z, Mershon, John, Mitlak, Bruce H, Powles, Trevor, Veronesi, Umberto, Vogel, Victor, Wickerham, D Lawrence
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lancet Publishing Group 2013
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3671272/ https://www.ncbi.nlm.nih.gov/pubmed/23639488 http://dx.doi.org/10.1016/S0140-6736(13)60140-3

Ejemplares similares

Barriers to preventive therapy for breast and other major cancers and strategies to improve uptake
por: DeCensi, Andrea, et al.
Publicado: (2015)

A Novel Automated Immunoassay Platform to Evaluate the Association of Adiponectin and Leptin Levels with Breast Cancer Risk
por: Macis, Debora, et al.
Publicado: (2021)

Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer
por: Richman, Juliet, et al.
Publicado: (2020)

Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial
por: Cuzick, Jack, et al.
Publicado: (2020)

Retrospective analysis of molecular scores for the prediction of distant recurrence according to baseline risk factors
por: Sestak, Ivana, et al.
Publicado: (2016)

Tamoxifen related side effects and their impact on breast cancer incidence: A retrospective analysis of the randomised IBIS-I trial
por: Hale, Michael J., et al.
Publicado: (2020)

Prevention of breast cancer using selective oestrogen receptor modulators (SERMs)
por: Powles, Trevor J
Publicado: (2006)

Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: effects on aromatase inhibition and oestrogen suppression.
por: MacNeill, F. A., et al.
Publicado: (1994)

Percutaneous trans-hepatic rescue and neo-creation of a post-surgical complete hepaticojejunostomy dehiscence
por: Rossi, Umberto Geremia, et al.
Publicado: (2021)

Factors Predicting Late Recurrence for Estrogen Receptor–Positive Breast Cancer
por: Sestak, Ivana, et al.
Publicado: (2013)

Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor–Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5
por: Dowsett, Mitch, et al.
Publicado: (2018)

Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials
por: Cuzick, Jack, et al.
Publicado: (2017)

Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I)
por: Smith, Samuel George, et al.
Publicado: (2017)

Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy
por: Buus, Richard, et al.
Publicado: (2016)

Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation
por: Gellert, Pascal, et al.
Publicado: (2016)

Molecular Drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study
por: Buus, Richard, et al.
Publicado: (2021)

Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor–positive breast cancers
por: Ribas, Ricardo, et al.
Publicado: (2014)

Prescribing tamoxifen in primary care for the prevention of breast cancer: a national online survey of GPs’ attitudes
por: Smith, Samuel G, et al.
Publicado: (2017)

Novel Treatments for Obesity: Implications for Cancer Prevention and Treatment
por: Cuttica, Carla Micaela, et al.
Publicado: (2023)

The effect of transdermal estradiol or oral conjugated oestrogen and fenretinide versus placebo on haemostasis and cardiovascular risk biomarkers in a randomized breast cancer chemoprevention trial
por: Lazzeroni, M, et al.
Publicado: (2008)

Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer
por: Buus, Richard, et al.
Publicado: (2018)

Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II
por: Sestak, I, et al.
Publicado: (2018)

Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial
por: Cuzick, Jack, et al.
Publicado: (2015)

Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor–Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial
por: Sestak, Ivana, et al.
Publicado: (2018)

The novel anti-oestrogen idoxifene inhibits the growth of human MCF-7 breast cancer xenografts and reduces the frequency of acquired anti-oestrogen resistance.
por: Johnston, S. R., et al.
Publicado: (1997)

The impact of body mass index on breast cancer incidence among women at increased risk: an observational study from the International Breast Intervention Studies
por: Smith, Samuel G., et al.
Publicado: (2021)

Markers for the identification of late breast cancer recurrence
por: Sestak, Ivana, et al.
Publicado: (2015)

Inflammatory and Metabolic Biomarker Assessment in a Randomized Presurgical Trial of Curcumin and Anthocyanin Supplements in Patients with Colorectal Adenomas
por: Macis, Debora, et al.
Publicado: (2023)

THE WOMEN'S HEALTH INITIATIVE (WHI): STILL LEARNING FROM 161,808 POSTMENOPAUSAL WOMEN
por: LaCroix, Andrea Z, et al.
Publicado: (2019)

ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
por: Pinhel, Isabel, et al.
Publicado: (2012)

Taste and Smell Disorders in Cancer Treatment: Results from an Integrative Rapid Systematic Review
por: Buttiron Webber, Tania, et al.
Publicado: (2023)

Oestrogens and oestrogen receptors in prostate cancer
por: Kowalska, Karolina, et al.
Publicado: (2016)

The involvement of the MAPK signalling pathway in the adaptation of MCF-7 cells to long-term oestrogen deprivation
por: Martin, L-A, et al.
Publicado: (2000)

Of Oestrogens and Sperm: A Review of the Roles of Oestrogens and Oestrogen Receptors in Male Reproduction
por: Dostalova, Pavla, et al.
Publicado: (2017)

Molecular changes in premenopausal oestrogen receptor-positive primary breast cancer in Vietnamese women after oophorectomy
por: Haynes, Ben P., et al.
Publicado: (2017)

Effect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer
por: Torrisi, R, et al.
Publicado: (2001)

Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial
por: Sestak, I, et al.
Publicado: (2012)

Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®
por: Buus, Richard, et al.
Publicado: (2021)

Plasma oestrogens and oestrogen receptors in breast cancer patients.
por: Mason, R. C., et al.
Publicado: (1985)

Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial
por: Forbes, John F, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ok3sqf8ovcqd2qr61f44gmenec